ACE2-targeted IL-27 gene therapy shows trend toward reduced SARS-CoV-2 pseudoviral entry in vitro

The global health crises caused by coronaviruses like SARS-CoV-2 highlight persistent limitations in preventing viral entry and effectively treating emerging variants, despite advancements in vaccines and antivirals. ACE2, the primary receptor for SARS-CoV-2, remains a crucial target for therapeutic intervention. Cell-based approaches, such as mesenchymal stromal cell therapies, have demonstrated safety and promise in clinical settings. Building on prior success with IL-27 gene therapy for acute respiratory distress syndrome, this study investigates ACE2-targeted IL-27 delivery as a novel strategy to inhibit SARS-CoV-2 entry.

Researchers developed an in vitro model utilizing SARS-CoV-2 spike pseudotyped lentivirus to simulate viral entry. Human adipose-derived stromal cells were electroporated with plasmid DNA encoding either ACE2-targeted IL-27 or non-targeted IL-27, and their conditioned media were collected. Two distinct regimens were evaluated: a "prevention" protocol, where cells were pre-treated with conditioned media prior to viral exposure, and a "treatment" protocol, where conditioned media and pseudotyped virus were added simultaneously. Viral entry was quantified using luciferase reporter activity and genome copy units in HEK293-ACE2 and A549-ACE2 cell lines.

The study observed that ACE2-targeted IL-27 exhibited a concentration-dependent trend towards reduced lentiviral entry. This effect was particularly noticeable in A549-ACE2 cells, suggesting a cell-type specific influence on the therapeutic response. While a clear trend was identified, the differences observed in viral entry reduction were not statistically significant. This indicates a proof-of-concept, but highlights the need for further optimization to achieve robust, quantifiable effects. The dual regimen approach, testing both "prevention" and "treatment" scenarios, provided initial insights into the potential timing of intervention. However, the abstract does not provide specific numerical reductions or p-values for the observed trends. The primary outcome, reduced viral entry, was assessed via luciferase reporter activity and genome copy units, confirming the methodology's ability to detect changes in pseudoviral infection. The lack of statistical significance underscores the preliminary nature of these findings.

ACE2-targeted IL-27 showed a concentration-dependent trend toward reduced lentiviral entry, particularly in A549-ACE2 cells, although differences were not statistically significant.